MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) invites investors to join a webinar with key opinion leaders to ...
March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global ...
Phase 1 Results SEP-631 was evaluated in a randomized, double-blind, placebo-controlled Phase 1 trial in healthy volunteers, including single-ascending dose, multiple-ascending dose and food-effect ...
TOKYO, March 01, 2026 (GLOBE NEWSWIRE) -- OrganTech, Inc. announced that its research team has defined a minimal stem cell set required for functional hair follicle regeneration in vitro, establishing ...
The platform is available in the UK from £19.95 per month and in Canada from $34.95 per month on flexible month-to-month subscriptions. Canadian practices signing up in 2026 can access a 50 percent ...
Positioned as the "value king of high-capacity fast-charging power banks," the CUKTECH 25SE perfectly addresses Malaysia's growing need for efficient and reliable power solutions. Its core strength ...
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN ® Peanut Patch increased their ...
Bezuclastinib demonstrates consistent biomarker and symptomatic improvement in patients with smoldering SM, a subgroup of NonAdvSM with high unmet need. As previously reported, bezuclastinib ...
Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before ...
The product is marketed toward adults — both men and women — who've experienced difficulty with weight management despite changes to diet and exercise routines. The recommended dosage listed on the ...
Zhou Feng, Chief Strategy Officer of Fangzhou, commented, “The collaboration represents both complementary strengths and a step toward building a new healthcare ecosystem,” adding that the company ...
In the U.S., a supplemental Biologics License Application (sBLA) has been accepted for review seeking approval for Dupixent in certain children aged 2 to 11 years with CSU. The U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results